[Method of onabotulinumtoxin type A injection in chronic migraine: the PREEMPT protocol in clinical practice].
Nina V LatyshevaM V NaprienkoElena FilatovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)
Chronic migraine (CM), a condition where patients experience over 15 days of headache per month, was identified as a separate disease in the International Classification of Headache Disorders 3-beta version. Onabotulinumtoxin type A was approved for the treatment of CM in 2010 after the completion of the extensive PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy) clinical program. The efficacy of onabotulinumtoxin type A was demonstrated in numerous studies in CM and medication-overuse headache. The paper focuses on the PREEMPT injection paradigm and provides guidance for successful and safe treatment of CM.
Keyphrases
- phase iii
- end stage renal disease
- clinical practice
- healthcare
- clinical trial
- open label
- machine learning
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- deep learning
- prognostic factors
- stem cells
- emergency department
- ultrasound guided
- combination therapy
- placebo controlled
- electronic health record
- mesenchymal stem cells